AR125306A1 - Método para la activación de las células t - Google Patents
Método para la activación de las células tInfo
- Publication number
- AR125306A1 AR125306A1 ARP220100863A ARP220100863A AR125306A1 AR 125306 A1 AR125306 A1 AR 125306A1 AR P220100863 A ARP220100863 A AR P220100863A AR P220100863 A ARP220100863 A AR P220100863A AR 125306 A1 AR125306 A1 AR 125306A1
- Authority
- AR
- Argentina
- Prior art keywords
- cells
- agonist
- hours
- activation
- less
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 18
- 230000004913 activation Effects 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 7
- 229940122738 CD3 agonist Drugs 0.000 abstract 6
- 229940123205 CD28 agonist Drugs 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 239000011324 bead Substances 0.000 abstract 4
- 238000004519 manufacturing process Methods 0.000 abstract 4
- 239000011159 matrix material Substances 0.000 abstract 4
- 230000003213 activating effect Effects 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 abstract 1
- 230000006044 T cell activation Effects 0.000 abstract 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporciona un método para la activación de células T que comprende el paso de la activación de células T en un medio que contiene un agonista de CD3 y/o un agonista de CD28 durante más de 36 horas y menos de 48 horas; un método para la producción de células T modificadas genéticamente, que comprende los pasos de la activación de las células T de acuerdo con el método de activación, la introducción de un gen exógeno en las células T activadas, y el cultivo de las células T en las cuales se ha introducido el gen exógeno; una población celular que comprende células T modificadas genéticamente obtenidas por medio del método de producción; y una matriz de cadenas poliméricas móviles o una perla que soporta un agonista de CD3 y/o un agonista de CD28, en el que la matriz o perla se utiliza para agregarse a un medio y el sometimiento de las células T a un paso de la activación durante más de 36 horas y menos de 48 horas. Reivindicación 1: Un método para la activación de células T caracterizado porque comprende el paso de la activación de células T en un medio que contiene un agonista de CD3 y/o un agonista de CD28 durante más de 36 horas y menos de 48 horas. Reivindicación 5: Un método para la producción de células T genéticamente modificadas, caracterizado porque comprende los pasos de: la activación de las células T de acuerdo con el método de activación de la reivindicación 1, la introducción de un gen exógeno en las células T activadas, y el cultivo de las células T en las cuales se ha introducido el gen exógeno. Reivindicación 6: Una población celular caracterizada porque comprende células T modificadas genéticamente obtenidas por medio del método de producción de acuerdo con la reivindicación 5. Reivindicación 8: Una matriz de cadenas poliméricas móviles o una perla que soporta un agonista de CD3 y/o un agonista de CD28, caracterizada porque la matriz o perla se utiliza para agregarse a un medio y el sometimiento de las células T a un paso de activación durante más de 36 horas y menos de 48 horas. Reivindicación 9: Un kit de activación de células T para la introducción de un gen exógeno, caracterizado porque comprende un agonista de CD3 y/o un agonista de CD28 soportado en un portador, y un manual que describe la activación de las células T en un medio que comprende el agonista de CD3 y/o el agonista de CD28 durante más de 36 horas y menos de 48 horas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021066050 | 2021-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125306A1 true AR125306A1 (es) | 2023-07-05 |
Family
ID=83546124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100863A AR125306A1 (es) | 2021-04-08 | 2022-04-07 | Método para la activación de las células t |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240191192A1 (es) |
| EP (1) | EP4321534A1 (es) |
| JP (1) | JPWO2022215718A1 (es) |
| KR (1) | KR20230167063A (es) |
| CN (1) | CN117136231A (es) |
| AR (1) | AR125306A1 (es) |
| AU (1) | AU2022255421A1 (es) |
| CA (1) | CA3216252A1 (es) |
| TW (1) | TW202305121A (es) |
| WO (1) | WO2022215718A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117660336A (zh) * | 2023-12-15 | 2024-03-08 | 北京同立海源生物科技有限公司 | 一种t细胞的活化方法及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200539890A (en) * | 2004-03-12 | 2005-12-16 | Brigham & Womens Hospital | Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
| WO2005096873A1 (de) | 2004-04-10 | 2005-10-20 | Henkel Kommanditgesellschaft Auf Aktien | Lockenwickler |
| EP2208786B1 (en) | 2005-12-13 | 2018-08-01 | Kyoto University | Nuclear reprogramming factor |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| US7661738B2 (en) | 2006-11-28 | 2010-02-16 | Veritainer Corporation | Radiation detection unit for mounting a radiation sensor to a container crane |
| WO2008124133A1 (en) | 2007-04-07 | 2008-10-16 | Whitehead Institute For Biomedical Research | Reprogramming of somatic cells |
| CN101802172A (zh) | 2007-05-30 | 2010-08-11 | 通用医疗公司 | 由体细胞产生多能细胞的方法 |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| EP2711418B1 (en) | 2012-09-25 | 2017-08-23 | Miltenyi Biotec GmbH | Method for polyclonal stimulation of T cells by flexible nanomatrices |
| WO2015120096A2 (en) * | 2014-02-04 | 2015-08-13 | Marc Better | Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof |
| CN114341348A (zh) * | 2019-09-03 | 2022-04-12 | 艾洛基治疗公司 | 制备用于t细胞疗法的t细胞的方法 |
-
2022
- 2022-04-07 TW TW111113286A patent/TW202305121A/zh unknown
- 2022-04-07 AU AU2022255421A patent/AU2022255421A1/en active Pending
- 2022-04-07 JP JP2023513040A patent/JPWO2022215718A1/ja active Pending
- 2022-04-07 WO PCT/JP2022/017224 patent/WO2022215718A1/ja active Application Filing
- 2022-04-07 CA CA3216252A patent/CA3216252A1/en active Pending
- 2022-04-07 EP EP22784700.1A patent/EP4321534A1/en active Pending
- 2022-04-07 CN CN202280025840.6A patent/CN117136231A/zh active Pending
- 2022-04-07 AR ARP220100863A patent/AR125306A1/es unknown
- 2022-04-07 KR KR1020237037420A patent/KR20230167063A/ko unknown
- 2022-04-07 US US18/554,372 patent/US20240191192A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2022215718A1 (es) | 2022-10-13 |
| CN117136231A (zh) | 2023-11-28 |
| CA3216252A1 (en) | 2022-10-13 |
| EP4321534A1 (en) | 2024-02-14 |
| TW202305121A (zh) | 2023-02-01 |
| KR20230167063A (ko) | 2023-12-07 |
| AU2022255421A1 (en) | 2023-10-26 |
| WO2022215718A1 (ja) | 2022-10-13 |
| US20240191192A1 (en) | 2024-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088395A (es) | Método de producción proteica utilizando compuestos anti-senescencia | |
| AR111785A2 (es) | Método in vitro de producción de eritrocitos | |
| AR125306A1 (es) | Método para la activación de las células t | |
| PE20060715A1 (es) | Proceso de produccion de anti - abeta | |
| DE50312269D1 (de) | Verfahren und vorrichtung zum züchten von zellen | |
| CO2022011682A2 (es) | Método para producir linfocitos citolíticos naturales a partir de células madre pluripotentes | |
| CO6241166A2 (es) | Metodos de produccion de proteinas utilizando compuestos anti-senectud | |
| NO20064379L (no) | Anvendelse av et serumfritt cellekulturmedium for produsjonen av IL-18BP i pattedyrceller | |
| GB2432846B (en) | Medium and culture of embryonic stem cells | |
| IL173103A (en) | Tiny bore, biochemical reactor and cell growth method | |
| DE60230677D1 (de) | Verfahren und materialien zur herstellung organischer produkte in zellen von candida-spezies | |
| ES2120946T3 (es) | Sistemas y medios de cultivo celular. | |
| NZ592159A (en) | Means and methods for influencing the stability of antibody producing cells | |
| DE602004030790D1 (de) | Verfahren und gerät zur herstellung von genetisch transformierbarem pflanzengewebe | |
| ATE525460T1 (de) | Verfahren zur kultivierung und vermehrung hämatopoetischer stammzellen und vorläuferzellen unter verwendung menschlicher endometriumzellen | |
| PE20221185A1 (es) | Metodos para mejorar el crecimiento celular con proteinas especificas de especie o genero y sus aplicaciones | |
| BR112022003852A2 (pt) | Métodos de preparação de células t para terapia de células t | |
| WO2003010304A3 (de) | Verfahren zur herstellung isolierter zellkulturen, kulturmedium zur kultivierung von zellkulturen und zellkultur | |
| CA2796599A1 (en) | Method for producing induced pluripotent stem cells | |
| AR043862A1 (es) | Procedimiento para la obtencion de estirpes celulares de mastocitos a partir de tejidos de cerdo y procedimiento para la produccion de moleculas de tipo de la heparina | |
| CL2021002711A1 (es) | Método de metanización en un biorreactor en condiciones de retención celular continua | |
| EP4235175A3 (en) | Methods for culturing human keratinocytes | |
| CA3101003A1 (fr) | Systeme de culture cellulaire en bioreacteur | |
| ES2482765T3 (es) | Células madre de Müller | |
| AR118617A1 (es) | Medios de cultivo celular que comprenden cetoácidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |